share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股sec公告 ·  04/19 13:23
Moomoo AI 已提取核心信息
Apollomics Inc., a biopharmaceutical company, has addressed a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's Division of Corporation Finance had issued a comment letter on April 15, 2024, seeking clarification on a discrepancy in the company's filing. The issue pertained to the residency of the board of directors, with the SEC noting conflicting information about the location of two directors. Apollomics has since amended the Registration Statement to reconcile the inconsistencies, confirming that all board members reside outside of China. The amendment was filed via EDGAR as Amendment No. 1, reflecting the company's response to the SEC's inquiry. White & Case LLP, representing Apollomics, has communicated the company's response and is open for further contact regarding the matter.
Apollomics Inc., a biopharmaceutical company, has addressed a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's Division of Corporation Finance had issued a comment letter on April 15, 2024, seeking clarification on a discrepancy in the company's filing. The issue pertained to the residency of the board of directors, with the SEC noting conflicting information about the location of two directors. Apollomics has since amended the Registration Statement to reconcile the inconsistencies, confirming that all board members reside outside of China. The amendment was filed via EDGAR as Amendment No. 1, reflecting the company's response to the SEC's inquiry. White & Case LLP, representing Apollomics, has communicated the company's response and is open for further contact regarding the matter.
生物制药公司Apollomics Inc. 已经回应了美国证券交易委员会（SEC）关于其最初于2024年4月1日提交的F-3表格注册声明的评论。美国证券交易委员会公司财务部于2024年4月15日发布了一封评论信，要求澄清该公司申报中的差异。该问题与董事会的居住地有关，美国证券交易委员会注意到有关两名董事所在地的信息相互矛盾。Apollomics此后修改了注册声明，以调和不一致之处，确认所有董事会成员都居住在中国境外。该修正案是通过EDGAR作为第1号修正案提交的，反映了该公司对美国证券交易委员会调查的回应。代表Apollomics的White & Case LLP已经传达了该公司的回应，并愿意就此事进行进一步接触。
生物制药公司Apollomics Inc. 已经回应了美国证券交易委员会（SEC）关于其最初于2024年4月1日提交的F-3表格注册声明的评论。美国证券交易委员会公司财务部于2024年4月15日发布了一封评论信，要求澄清该公司申报中的差异。该问题与董事会的居住地有关，美国证券交易委员会注意到有关两名董事所在地的信息相互矛盾。Apollomics此后修改了注册声明，以调和不一致之处，确认所有董事会成员都居住在中国境外。该修正案是通过EDGAR作为第1号修正案提交的，反映了该公司对美国证券交易委员会调查的回应。代表Apollomics的White & Case LLP已经传达了该公司的回应，并愿意就此事进行进一步接触。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息